Skip to content

Efficacy and safety of magnesium alloy-based long-acting hydrogen-releasing ointment in the treatment of male pattern androgenic alopecia

Efficacy and safety of magnesium alloy-based long-acting hydrogen-releasing ointment in the treatment of male pattern androgenic alopecia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099246
Enrollment
Unknown
Registered
2025-03-20
Start date
2025-04-07
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male androgen alopecia

Interventions

minoxidil spray group:Participants applied 5% minoxidil tincture spray twice daily, morning and evening, administering the solution evenly across the observed area.
Magnesium alloy base long-acting hydrogen release ointment treatment group:Apply the ointment twice daily, morning and evening, using 2 grams of Ointment A and 2 grams of Ointment B. Ensure thorough m

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. All are diagnosed outpatient male patients with androgenetic alopecia (AGA patients with Type III vertex, Type IV, and Type V); 2. Aged between 20 and 65 years (inclusive); 3. Patients are in good general health, without systemic diseases (such as heart, psychiatric, or scalp diseases); 4. Voluntarily participate in the clinical trial and sign a written informed consent form; 5. Maintain the same hair color, hairstyle, and hair length during the study period.

Exclusion criteria

Exclusion criteria: 1. Patients with scalp wounds or infections; Individuals with severe heart, lung, liver, and kidney dysfunction are deemed unsuitable for inclusion by the researchers; 2. Have used any drugs that may affect hair growth (such as anti androgen drugs, anti hypertensive drugs, hormones, cytotoxic drugs, etc.) within the 18 months prior to enrollment in this trial; 3. Patients allergic to minoxidil; 4. Those who cannot be followed up on time; 5. Some researchers believe that conditions such as hair pulling addiction are not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Terminal hair density difference;

Secondary

MeasureTime frame
Total hair density value;Physician's assessment score for clinical improvement.;Patient's self-assessment score for clinical improvement.;Patient satisfaction score.;

Countries

China

Contacts

Public ContactYali Yang

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

1965559353@qq.com+86 158 0189 1767

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026